All In Biotech

Drug Trial Radar · NCT04411654

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Jun 29, 2021

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Prevail TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 months, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

Conditions

  • Gaucher Disease, Type 2

Interventions

  • LY3884961Genetic

    Participants will receive a single dose of LY3884961 administered intracisternally.

  • MethylprednisoloneDrug

    Single IV pulse administered as concomitant medication.

  • SirolimusDrug

    Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.

  • PrednisoneDrug

    Administered orally as concomitant medication, followed by dose tapering.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuationTime frame: Year 5
  2. Immunogenicity of AAV9 and GCase in bloodTime frame: Up to Year 2
  3. Immunogenicity of AAV9 and GCase in CSFTime frame: Up to Year 1

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital, 747 52nd St

    Oakland, California

  • University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue

    Minneapolis, Minnesota

  • NYU Medical Center, 305 Second Ave, Suite 16

    New York, New York

  • Children's Hospital of Pittsburgh, 4401 Penn Avenue

    Pittsburgh, Pennsylvania

  • Lysosomal & Rare Disorders Research and Treatment Center

    Fairfax, Virginia

  • Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.